Looking at harm minimisation

Naloxone, hazardous use of alcohol and treatment inequity: part two of our expert discussion of the latest in harm minimisation Why is the naloxone program not seeing wider take-up? Should pharmacists be able to inject buprenorphine? Should pharmacies be able to offer drug testing? Are pharmacies offering stigma-free methadone provision? Regular AJP contributor and leading addiction medicine